The executive pyramid at Johnson & Johnson is going through a significant revamp with head of pharmaceuticals Joaquin Duato taking on most of the responsibilities held by Group Worldwide Chairman Sandra Peterson as she prepares to retire.
Duarto will become a vice chairman of the executive committee on July 2. The pharma unit that Duato currently oversees is already the largest, but he will add J&J’s consumer business along with responsibility for supply chain, IT, global services, and the health and wellness businesses.
The moves come after Duarto and Peterson last year nabbed $9 million each in retention bonuses.
Along with Duarto, the company promoted Paul Stoffels, M.D., to a vice chairman of the executive committee. Stoffels will oversee pharma R&D, be chief medical officer and be responsible for several other areas. There were several other shifts as well.
“These appointments recognize the enormous talent among the senior leadership team of Johnson & Johnson, and will ensure our continued focus on delivering on our commitments to patients, consumers, employees, our communities and our shareholders,” CEO and Chairman Alex Gorsky Gorsky said in a statement.
Among Duarto’s accomplishments outlined in J&J’s proxy that had justified his pay was his leadership in the $30 billion buyout of Actelion, as well as beating J&J’s financial goals for its pharmaceutical unit. Duato has been J&J’s EVP of Pharma since April 2016 and worldwide chairman since 2011.
Among the challenges Duarto faces with his new responsibilities is maintaining faith in J&J’s consumer products in the face of thousands of lawsuits alleging J&J’s talcum powders caused cancer.
Peterson will leave Oct. 1. She was brought on in 2012 after Gorsky got frustrated with manufacturing issues in the consumer business that resulted in the recall of tens of millions of consumer products at a reported cost of $1.6 billion. After straightening out issues there, she was rewarded last year with responsibility of the troubled medical devices unit.
By Eric Palmer
Source: Fierce Pharma
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
